Last reviewed · How we verify

Vedic Lifesciences Pvt. Ltd. — Portfolio Competitive Intelligence Brief

Vedic Lifesciences Pvt. Ltd. pipeline: 1 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 3 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Lactobacillus Species Lactobacillus Species marketed Probiotic Gastroenterology
A. Paniculata A. Paniculata phase 3 Herbal extract / Botanical immunomodulator Immunology / Respiratory / Infectious Disease
A. Chilensis A. Chilensis phase 3
A. Paniculata and A. Chilensis A. Paniculata and A. Chilensis phase 3 Herbal immunomodulator Immunology / Inflammation

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Seoul National University Hospital · 2 shared drug classes
  2. Biocodex · 1 shared drug class
  3. Federico II University · 1 shared drug class
  4. CHU de Quebec-Universite Laval · 1 shared drug class
  5. Chuncheon Sacred Heart Hospital · 1 shared drug class
  6. Dow University of Health Sciences · 1 shared drug class
  7. CD Pharma India Pvt. Ltd. · 1 shared drug class
  8. BioBalance Corporation · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Vedic Lifesciences Pvt. Ltd.:

Cite this brief

Drug Landscape (2026). Vedic Lifesciences Pvt. Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/vedic-lifesciences-pvt-ltd. Accessed 2026-05-16.

Related